급성 허혈성 뇌졸중 : 시장 인사이트, 역학, 시장 예측(2034년)

Acute Ischemic Stroke - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,807,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 17,711,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 23,614,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 35,422,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

급성 허혈성 뇌졸중 시장 규모는 2023년 미국이 주요 7개국 중 가장 큰 시장으로 약 8억 100만 달러로 2034년까지 연평균 11% 성장할 것으로 예상되며, 2023년 급성 허혈성 뇌졸중으로 진단된 환자 수는 미국이 7개국 중 가장 많은 75만 4,000명으로 가장 많았습니다. 4,000건으로 2034년까지 더욱 증가할 것으로 예상됩니다. 미국에서는 2023년 남성 37만 6,000명, 여성 37만 8,000명이 급성 허혈성 뇌졸중을 앓았습니다.

급성 허혈성 뇌졸중 시장은 혈전제거술의 발전, 생활습관 요인으로 인한 이환율 증가, 뇌졸중 치료에 대한 재정적 지원 등이 시장을 주도하고 있습니다. 장벽으로는 제한된 치료 기간, 높은 비용, 낮은 인지도 등을 들 수 있습니다. 미충족 수요에는 진단 개선, 치료 기간 연장, 신경 보호, 뇌졸중 후 재활 개선 등이 있습니다.

현재 급성 허혈성 뇌졸중 치료제 시장은 항혈소판제, 항응고제, 조직 플라스미노겐 활성화제(tPA), 에다라본, 지질저하제 등으로 구성되어 있습니다. 그러나 이 시장은 치료의 폭이 좁고, 진단 지연, 전문 치료 접근성 제한, 안전성 우려, 높은 비용, 규제적 장애 등 큰 문제에 직면해 있습니다. 이러한 문제들은 조기 발견의 개선, 사회 교육, 보다 효과적이고 접근하기 쉬운 치료법의 필요성을 강조하고 있습니다.

급성 허혈성 뇌졸중(Acute Ischemic Stroke: AIS)은 뇌에 혈액을 공급하는 혈관이 막혀 혈류가 감소하고 산소가 부족해지면서 발생합니다. 이 막힘은 일반적으로 좁아진 동맥(죽상동맥경화증)에서 형성되거나 심장이나 체내 다른 곳에서 이동한 혈전에 의해 발생합니다. 그 결과 산소와 영양분이 부족해져 뇌세포가 사멸하고 마비, 언어장애, 인지장애 등의 신경장애가 발생합니다. 혈류를 회복하고 뇌 손상을 최소화하기 위해서는 정맥내 혈전 용해 요법이나 기계적 혈전 제거술과 같은 즉각적인 의료적 개입이 중요하며, AIS의 위험 요인으로는 고혈압, 당뇨병, 흡연, 비만 등이 있습니다.

급성 허혈성 뇌졸중을 진단하기 위해서는 임상 평가와 영상 진단의 조합이 필요합니다. 환자는 종종 갑작스러운 신경학적 증상, 예를 들어 쇠약, 언어장애, 시각장애를 보이는 경우가 많으며, NIH 뇌졸중 척도(NIHSS)를 이용한 신속한 평가는 뇌졸중의 심각성을 판단하는 데 도움이 됩니다. 컴퓨터단층촬영(CT) 검사나 자기공명영상(MRI) 검사는 허혈성 뇌졸중과 출혈성 뇌졸중을 감별하고, 뇌의 손상된 부위와 허혈의 유무를 파악하는 데 매우 중요합니다. 또한 CT 혈관조영술이나 MR 혈관조영술과 같은 혈관 영상 기술은 혈관의 막힘을 평가하고 적절한 치료 전략을 수립하는 데 사용됩니다.

급성 허혈성 뇌졸중(AIS)의 치료는 뇌의 환부에 대한 혈류를 신속하게 회복시키는 데 중점을 둡니다. 주요 치료법은 혈전을 용해시키는 조직 플라스미노겐 활성제(tPA)를 이용한 혈전 용해 요법으로, 증상 발현 후 4.5시간 이내에 투여하는 것이 가장 효과적입니다. 기계적 혈전제거술은 특수 기구를 이용하여 혈전을 물리적으로 제거하는 치료법으로, 특히 뇌졸중 발병 후 24시간 이내에 시행할 경우 효과적입니다. 조기 진단과 신속한 치료는 뇌손상을 최소화하고 회복 결과를 개선하는 데 매우 중요합니다. 기타 치료로는 항혈소판제, 항응고제, 뇌졸중 치료실에서의 지지요법 등이 있습니다.

주요 7개국 급성 허혈성 뇌졸중 시장에 대해 조사했으며, 시장 개요, 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 미충족 의료 수요 등을 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 리포트 서론

제3장 급성 허혈성 뇌졸중 시장 개요

제4장 역학과 시장 예측의 조사 방법

제5장 주요 이벤트

제6장 개요

제7장 질환의 배경과 개요

• 서론
• 징후와 증상
• 급성 허혈성 뇌졸중 단계와 임상 증상
• 원인
• 병인
• 급성 허혈성 뇌졸중의 진단
• 감별 진단
• 치료와 관리

제8장 급성 허혈성 뇌졸중 역학과 환자 인구

• 주요 조사 결과 : 역학
• 전제와 근거 : 주요 7개국
• 주요 7개국에서 급성 허혈성 뇌졸중의 발증례 수
• 주요 7개국에서 급성 허혈성 뇌졸중의 진단 증례 총수
• 미국
• EU4개국과 영국
• 일본

제9장 급성 허혈성 뇌졸중 환자 동향

제10장 급성 허혈성 뇌졸중의 출시 약제

제11장 신규 약제

제12장 급성 허혈성 뇌졸중 시장 : 주요 7개국 시장 분석

• 주요 조사 결과
• 주요 시장 예측의 전제조건
• 급성 허혈성 뇌졸중 시장 전망
• 주요 7개국에서 급성 허혈성 뇌졸중 전체의 시장 규모
• 주요 7개국에서 급성 허혈성 뇌졸중 치료제의 시장 규모
• 미국
• EU4개국과 영국
• 일본

제13장 주요 업계 리더의 견해

제14장 급성 허혈성 뇌졸중 SWOT 분석

제15장 급성허혈성 미충족 요구

제16장 급성 허혈성 뇌졸중 시장 접근과 상환

• 미국
• EU4개국과 영국
• 일본

제17장 부록

제18장 리포트의 조사 방법

제19장 DelveInsight의 서비스 내용

제20장 면책사항

KSA

영문 목차

영문목차

Key Highlights:

• In 2023, the Acute ischemic stroke market size was highest in the US among the 7MM, accounting for approximately USD 801 million which is further expected to increase by 2034 at a CAGR of 11%.
• In 2023, the diagnosed incidence of Acute Ischemic Stroke was highest in the US among the 7MM, accounting for nearly 754 thousand cases which is further expected to increase by 2034.
• In the United States, in 2023, ~376 thousand males and ~378 thousand females were affected with acute ischemic stroke.
• The Acute ischemic stroke market is driven by advancements in thrombectomy, increasing incidence due to lifestyle factors, and funding for stroke care. Barriers include limited treatment windows, high costs, and a lack of awareness. Unmet needs encompass improved diagnostics, extended treatment windows, neuroprotection, and better post-stroke rehabilitation.
• The current Acute ischemic stroke treatment market comprises antiplatelets, anticoagulants, tissue plasminogen activator (tPA), edaravone, and lipid-lowering agents. However, this market faces substantial challenges, such as a narrow treatment window, delayed diagnosis, limited access to specialized care, safety concerns, high costs, and regulatory obstacles. These issues highlight the critical need for improved early detection, public education, and more effective, accessible therapies.
• Glenzocimab's ACTISAVE trial, a Phase II/III efficacy study, recruited participants from seven European countries, Israel, the UK, and the USA. The results from the 400-patient ACTISAVE study were presented at the European Stroke Organization Conference (ESOC) in May 2024.
• The Acute ischemic stroke market size in Japan was USD 122 million in 2023, which is expected to rise by 2034.

DelveInsight's "Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the acute ischemic stroke, historical and forecasted epidemiology as well as the Acute Ischemic Stroke market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain), the United Kingdom, and Japan.

The Acute Ischemic Stroke market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Ischemic Stroke market size from 2020 to 2034. The report also covers current Acute Ischemic Stroke treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Acute Ischemic Stroke Treatment Market

Acute Ischemic Stroke Overview

Acute Ischemic Stroke (AIS) occurs when a blood vessel supplying the brain is blocked, leading to reduced blood flow and oxygen deprivation. This blockage is typically caused by a blood clot, often forming in narrowed arteries (atherosclerosis) or traveling from the heart or elsewhere in the body. The resulting lack of oxygen and nutrients causes brain cells to die, resulting in neurological deficits such as paralysis, speech difficulties, and cognitive impairments. Immediate medical intervention, such as intravenous thrombolysis or mechanical thrombectomy, is crucial to restore blood flow and minimize brain damage. Risk factors for AIS include hypertension, diabetes, smoking, and obesity.

Acute Ischemic Stroke Diagnosis

The diagnosis of acute Ischemic Stroke involves a combination of clinical evaluation and imaging techniques. Patients often present with sudden neurological symptoms such as weakness, speech difficulties, or visual disturbances. Rapid assessment using the NIH Stroke Scale (NIHSS) helps determine stroke severity. Computed Tomography (CT) scans or Magnetic Resonance Imaging (MRI) are crucial for differentiating Ischemic Stroke from hemorrhagic stroke, as well as identifying the affected brain region and the presence of ischemia. Additionally, vascular imaging techniques like CT angiography or MR angiography are used to assess blood vessel blockages, guiding appropriate treatment strategies.

Acute Ischemic Stroke Treatment

Treatment of acute Ischemic Stroke (AIS) focuses on rapidly restoring blood flow to the affected area of the brain. The primary treatments are thrombolytic therapy with tissue plasminogen activator (tPA), which dissolves blood clots and is most effective when administered within 4.5 hours of symptom onset. Mechanical thrombectomy, a procedure that physically removes clots using specialized devices, is another option for eligible patients, particularly when performed within 24 hours of stroke onset. Early diagnosis and prompt treatment are crucial in minimizing brain damage and improving recovery outcomes. Additional treatments may include antiplatelet agents, anticoagulants, and supportive care in a stroke unit.

Acute Ischemic Stroke Epidemiology

As the Acute ischemic stroke market is derived using a patient-based model, the Acute Ischemic Stroke epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Incident Cases of Acute Ischemic Stroke, Gender-specific Cases of Acute Ischemic Stroke, Age-specific Cases of Acute Ischemic Stroke, and Type-specific Cases of Acute Ischemic Stroke in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

• In the assessment done by DelveInsight, the estimated total diagnosed incident cases of Acute Ischemic Stroke in the 7MM were nearly 1,640 thousand in 2023.
• The highest total diagnosed incident cases of Acute Ischemic Stroke were accounted by the US in 2023 (754 thousand), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed incident cases of Acute Ischemic Stroke with ~265 thousand cases in 2023. On the other hand, Spain had the lowest incident population (60 thousand cases).
• Japan had nearly 236 thousand total diagnosed incident cases of Acute Ischemic Stroke in 2023, accounting for approximately 14% in 7MM.
• The incident cases of acute ischemic stroke (AIS) in Japan in 2023 were categorized by type, including large-artery atherosclerosis, small artery occlusions, cardioembolism, and other/undetermined causes. Among these, cardioembolism had the highest incidence, with around 77 thousand cases reported.
• The cases were divided by age into four groups: 0-64 years, 65-74 years, 75-84 years, and 85+ years. In the EU4 and the UK, the highest number of cases in 2023 occurred in the 75-84 years age group, with approximately 200,000 cases reported.

Recent Developments in Acute Ischemic Stroke Clinical Trials

• On October 30, 2024, Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for treating acute ischemic stroke (AIS). PP-007 is currently undergoing safety and efficacy evaluation in the ongoing U.S.-based clinical trial, HEMERA-1.
• On October 22, 2024, Remedy Pharmaceuticals, a leader in stroke drug development, announced that the FDA's Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA to treat large territory acute ischemic stroke, including large hemispheric infarctions (LHI).

Acute Ischemic Stroke Drug Chapters

The drug chapter segment of the Acute Ischemic Stroke market report encloses a detailed analysis of Acute Ischemic Stroke off-label drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps to understand the Acute Ischemic Stroke clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Acute Ischemic Stroke Emerging Drugs

Glenzocimab (ACT017): Acticor Biotech

Glenzocimab (ACT017) is a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). It inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain. GPVI is expressed exclusively by platelets and their precursors, megakaryocytes. It is a key receptor on platelets for polymerized fibrin, fibrinogen, and collagen. GPVI interaction with its ligands triggers platelet activation, leading to aggregation, the recruitment of additional platelets, and promoting coagulation. GPVI blockade has demonstrated efficient antithrombotic potential in experimental thrombosis models without increasing bleeding.

Glenzocimab is in advanced clinical development for Acute Ischemic Stroke and myocardial infarction, with mixed results from ongoing trials.

LT3001: Lumosa Therapeutics

LT3001 is a novel small molecule for the treatment of acute ischemic stroke. It is a novel molecule composed of a synthetic peptide and a free radical scavenger and has demonstrated recanalization capabilities without the increased risk of hemorrhagic transformation. The peptide moiety is modified from the degradation products of fibrinogen, and it blocks the binding between platelet and fibrinogen, the two major components of thrombus. The small molecule portion is an antioxidant designed to limit oxidative stress and protect tissues from ischemia/reperfusion injury. Additionally, at the thrombosis site, it safely restores blood vessel patency by promoting the local endogenous fibrinolysis activity, enhancing plasminogen binding to the fibrin clot and facilitating the activation of plasminogen to plasmin while simultaneously protecting the tissues from free radicals and inflammation-mediated injury.

LT3001 has shown promising results in its Phase IIa trial, meeting its primary safety endpoint and demonstrating neurological improvement in Acute Ischemic Stroke patients.

Acute Ischemic Stroke Market Outlook

Acute Ischemic Stroke (AIS) is a critical medical condition caused by a sudden blockage in a blood vessel supplying the brain, leading to a loss of blood flow and oxygen to the affected brain region. Rapid treatment is essential to minimize brain damage and improve outcomes.

The primary treatment for AIS involves restoring blood flow to the brain as quickly as possible. The mainstay of pharmacological treatment is intravenous thrombolysis with tissue plasminogen activator (tPA), such as alteplase. tPA works by dissolving the blood clot blocking the artery and must be administered within 4.5 hours of stroke onset to be most effective. Beyond this time frame, the risks of bleeding complications increase significantly.

For patients with large artery occlusions, mechanical thrombectomy has emerged as a highly effective treatment option. This minimally invasive procedure involves inserting a catheter through the blood vessels to the site of the blockage, where a device like a stent retriever or aspiration catheter removes or breaks up the clot. Mechanical thrombectomy can be performed within 24 hours of symptom onset and is often used in conjunction with tPA.

Additional treatments for Acute ischemic stroke may include antiplatelet agents, anticoagulants, and supportive care to manage blood pressure, blood sugar, and other vital parameters. Post-stroke rehabilitation, involving physical, occupational, and speech therapies, is crucial for maximizing recovery and improving the quality of life for stroke survivors.

• The Acute ischemic stroke market size in the 7MM was ~USD 1,296 million in 2023, which is further anticipated to increase during the forecast period.
• The United States accounted for the highest Acute ischemic stroke market size approximately 62% of the total Acute ischemic stroke market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Among the EU countries, Germany had the highest Acute ischemic stroke market size with nearly USD 150 million in 2023, while Spain had the lowest Acute ischemic stroke market size with USD ~34 million in 2023.
• The Acute ischemic stroke market size in Japan was estimated to be about USD 122 million in 2023.
• With the expected launch of upcoming Acute ischemic stroke therapies, such as Glenzocimab (ACT017), LT3001, and DM199, among others, the total Acute ischemic stroke market size is expected to show change in the upcoming years.

Acute Ischemic Stroke Drugs Uptake

This section focuses on the uptake rate of potential Acute ischemic stroke drugs expected to launch in the market during 2020-2034. For example, DM199 in the US is expected to be launched by 2025 with a peak share of 2.88%. DM199 is anticipated to take 7 years to peak with a medium uptake.

Acute Ischemic Stroke Pipeline Development Activities

The Acute ischemic stroke market report provides insights into different Acute Ischemic Stroke clinical trials within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Acute ischemic stroke market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Acute Ischemic Stroke emerging therapies.

Acute ischemic stroke KOL Views

To keep up with current Acute ischemic stroke market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Acute Ischemic Stroke evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Medical University of South Carolina, US; Sapienza University of Rome, Italy; University of Duisburg-Essen, Germany; Hopital Lariboisiere, France; Vall d'Hebron University Hospital, Spain; University College London Hospitals, UK and Kyoto University Hospital, Japan; and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Acute Ischemic Stroke market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Acute ischemic stroke Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The Acute ischemic stroke market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Acute Ischemic Stroke Market Report

• The Acute ischemic stroke market report covers a segment of key events, an executive summary, descriptive overview of acute ischemic stroke, explaining its causes, signs and symptoms, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Acute Ischemic Stroke market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The Acute ischemic stroke market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Acute Ischemic Stroke market.

Acute Ischemic Stroke Market Report Insights

• Acute Ischemic Stroke Patient Population
• Acute Ischemic Stroke Therapeutic Approaches
• Acute Ischemic Stroke Pipeline Analysis
• Acute Ischemic Stroke Market Size
• Acute ischemic stroke Market Trends
• Existing and Future Acute ischemic stroke Market Opportunity

Acute Ischemic Stroke Market Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Acute Ischemic Stroke Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Acute Ischemic Stroke Drugs Uptake
• Key Acute Ischemic Stroke Market Forecast Assumptions

Acute Ischemic Stroke Market Report Assessment

• Current Acute Ischemic Stroke Treatment Practices
• Acute Ischemic Stroke Unmet Needs
• Acute Ischemic Stroke Pipeline Product Profiles
• Acute Ischemic Stroke Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Acute Ischemic Stroke Market Drivers
• Acute Ischemic Stroke Market Barriers

Key Questions Answered In The Acute ischemic stroke Market Report

Acute Ischemic Stroke Market Insights

• What was the Acute Ischemic Stroke market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Acute Ischemic Stroke market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Acute Ischemic Stroke market size during the forecast period (2024-2034)?
• At what CAGR, the Acute Ischemic Stroke market is expected to grow at the 7MM level during the forecast period (2024-2034)?
• What would be the Acute Ischemic Stroke market outlook across the 7MM during the forecast period (2024-2034)?
• What would be the Acute Ischemic Stroke market growth till 2034 and what will be the resultant market size in the year 2034?
• How would the market drivers, barriers, and future opportunities affect the Acute ischemic stroke market dynamics and subsequent analysis of the associated trends?

Acute Ischemic Stroke Epidemiology Insights

• What is the disease risk, burden, and unmet needs of acute ischemic stroke?
• What is the historical Acute Ischemic Stroke patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient population of Acute Ischemic Stroke at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to acute ischemic stroke?
• Out of the above-mentioned countries, which country would have the highest incident population of Acute Ischemic Stroke during the forecast period (2024-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2024-2034)?

Current Acute Ischemic Stroke Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Acute Ischemic Stroke along with the approved therapy?
• What are the current treatment guidelines for the treatment of Acute Ischemic Stroke in the US, Europe, And Japan?
• What are the Acute Ischemic Stroke marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of acute ischemic stroke?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of acute ischemic stroke?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke therapies?
• What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Ischemic Stroke and their status?
• What are the key designations that have been granted for the emerging therapies for acute ischemic stroke?
• What are the 7MM historical and forecasted Acute ischemic stroke market?

Reasons to Buy Acute Ischemic Stroke Market Report

• The Acute ischemic stroke market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Acute Ischemic Stroke Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing Acute ischemic stroke market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming Acute ischemic stroke companies in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging Acute ischemic stroke therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
• Detailed insights on the unmet need of the existing Acute ischemic stroke market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The Acute Ischemic Stroke Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Acute Ischemic Stroke market?

The Acute Ischemic Stroke market is quite robust. The major layers are Acticor Biotech, Lumosa Therapeutics, DiaMedica Therapeutics Inc., and others which are currently developing drugs for the treatment of acute ischemic stroke.

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Acute Ischemic Stroke market?

The increase in diagnosed incident cases of Acute Ischemic Stroke and the launch of emerging therapies are attributed to be the key drivers for increasing the Acute Ischemic Stroke market.

5. What is the expected impact of emerging therapies or advancements in Acute Ischemic Stroke treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Acute Ischemic Stroke treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Acute Ischemic Stroke market.

Table of Contents

1 Key Insights

2 Report Introduction

3 Acute ischemic stroke Market Overview at a Glance

• 3.1 Market Share (%) Distribution of Acute ischemic stroke by Therapies in 2020
• 3.2 Market Share (%) Distribution of Acute ischemic stroke by Therapies in 2034

4 Epidemiology and Market Forecast Methodology

5 Key Events

6 Executive Summary

7 Disease Background and Overview

• 7.1 Introduction
• 7.2 Signs and Symptoms
• 7.3 Stages and Clinical presentation of Acute ischemic stroke
• 7.4 Causes
• 7.5 Pathogenesis
• 7.6 Acute ischemic stroke Diagnosis
  • 7.6.1 Diagnostic Algorithm
  • 7.6.2 Diagnostic Approach
  • 7.6.3 Diagnostic Recommendations
• 7.7 Differential Diagnosis
• 7.8 Treatment and Management
  • 7.8.1 General Management
  • 7.8.2 Surgical Management
  • 7.8.3 Treatment Algorithm
  • 7.8.4 Treatment Recommendations

8 Epidemiology and Patient Population of Acute ischemic stroke

• 8.1 Key Findings: Epidemiology
• 8.2 Assumptions and Rationale: 7MM
• 8.3 Total Incident Cases of Acute ischemic stroke in the 7MM
• 8.4 Total Diagnosed Incident Cases of Acute ischemic stroke in the 7MM
• 8.5 The United States
  • 8.5.1 Total Diagnosed Incident Cases of Acute ischemic stroke in the United States
  • 8.5.2 Age-specific cases of Acute Ischemic Stroke in the United States
  • 8.5.3 Gender-specific Cases of Acute ischemic stroke in the United States
  • 8.5.4 Type-specific cases of Acute Ischemic Stroke in the United States
• 8.6 EU4 and the UK
  • 8.6.1 Germany
    • 8.6.1.1 Total Diagnosed Incident Cases of Acute ischemic stroke
    • 8.6.1.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.1.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.1.4 Type-specific cases of Acute Ischemic Stroke
  • 8.6.2 France
    • 8.6.2.1 Total Diagnosed Incident Cases of Acute ischemic stroke
    • 8.6.2.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.2.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.2.4 Type-specific cases of Acute Ischemic Stroke
  • 8.6.3 Italy
    • 8.6.3.1 Total Diagnosed Incident Cases of Acute ischemic stroke
    • 8.6.3.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.3.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.3.4 Type-specific cases of Acute Ischemic Stroke
  • 8.6.4 Spain
    • 8.6.4.1 Total Diagnosed Incident Cases of Acute ischemic stroke in Japan
    • 8.6.4.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.4.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.4.4 Type-specific cases of Acute Ischemic Stroke
  • 8.6.5 The United Kingdom
    • 8.6.5.1 Total Diagnosed Incident Cases of Acute ischemic stroke
    • 8.6.5.2 Age-specific cases of Acute Ischemic Stroke
    • 8.6.5.3 Gender-specific Cases of Acute ischemic stroke
    • 8.6.5.4 Type-specific cases of Acute Ischemic Stroke
• 8.7 Japan
  • 8.7.1 Total Diagnosed Incident Cases of Acute ischemic stroke
  • 8.7.2 Age-specific cases of Acute Ischemic Stroke in Japan
  • 8.7.3 Gender-specific Cases of Acute ischemic stroke in Japan
  • 8.7.4 Type-specific cases of Acute Ischemic Stroke in Japan

9 Acute ischemic stroke Patient Journey

10 Acute ischemic stroke Marketed Drug

• 10.1 BRILINTA (ticagrelor): AstraZeneca
  • 10.1.1 Product Description
  • 10.1.2 Regulatory milestone
  • 10.1.3 Other Developmental Activities
  • 10.1.4 Clinical Trials Information
  • 10.1.5 Safety and Efficacy
  • 10.1.6 Analysts' Views

11. Emerging Drugs

• 11.1 Key Cross Competition
• 11.2 Glenzocimab (ACT017): Acticor Biotech
  • 11.2.1 Product Description
  • 11.2.2 Other Developmental Activities
  • 11.2.3 Clinical Trials Information
  • 11.2.4 Safety and Efficacy
  • 11.2.5 Analysts' Views
• 11.3 LT3001: Lumosa Therapeutics
  • 11.3.1 Product Description
  • 11.3.2 Other Developmental Activities
  • 11.3.3 Clinical Trials Information
  • 11.3.4 Safety and Efficacy
  • 11.3.5 Analysts' Views
• 11.4 DM199: DiaMedica Therapeutics
  • 11.4.1 Product Description
  • 11.4.2 Other Developmental Activities
  • 11.4.3 Clinical Trials Information
  • 11.4.4 Safety and Efficacy
  • 11.4.5 Analysts' Views

12 Acute ischemic stroke Market: 7 Major Market Analysis

• 12.1 Key Findings
• 12.2 Key Market Forecast Assumptions
• 12.3 Acute ischemic stroke Market Outlook
• 12.4 Total Market Size of Acute ischemic stroke in the 7MM
• 12.5 Market Size of Acute ischemic stroke by Therapies in the 7MM
• 12.6 The United States
  • 12.6.1 Total Market Size of Acute ischemic stroke
  • 12.6.2 Market Size of Acute ischemic stroke by Therapies
• 12.7 EU4 and the UK
  • 12.7.1 Germany
    • 12.7.1.1 Total Market Size of Acute ischemic stroke
    • 12.7.1.2 Market Size of Acute ischemic stroke by Therapies
  • 12.7.2 France
    • 12.7.2.1 Total Market Size of Acute ischemic stroke
    • 12.7.2.2 Market Size of Acute ischemic stroke by Therapies
  • 12.7.3 Italy
    • 12.7.3.1 Total Market Size of Acute ischemic stroke
    • 12.7.3.2 Market Size of Acute ischemic stroke by Therapies
  • 12.7.4 Spain
    • 12.7.4.1 Total Market Size of Acute ischemic stroke
    • 12.7.4.2 Market Size of Acute ischemic stroke by Therapies
  • 12.7.5 The United Kingdom
    • 12.7.5.1 Total Market Size of Acute ischemic stroke
    • 12.7.5.2 Market Size of Acute ischemic stroke by Therapies
• 12.8 Japan
  • 12.8.1 Total Market Size of Acute ischemic stroke
  • 12.8.2 Market Size of Acute ischemic stroke by Therapies

13 Key Opinion Leaders' Views

14 Acute ischemic stroke SWOT Analysis

15 Acute ischemic stroke Unmet Needs

16 Acute ischemic stroke Market Access and Reimbursement

• 16.1 The United States
  • 16.1.1 Centre for Medicare and Medicaid Services (CMS)
• 16.2 In EU4 and the UK
  • 16.2.1 Germany
  • 16.2.2 France
  • 16.2.3 Italy
  • 16.2.4 Spain
  • 16.2.5 The United Kingdom
• 16.3 Japan
  • 16.3.1 MHLW

17 Appendix

• 17.1 Bibliography
• 17.2 Acronyms and Abbreviations

18 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

관련자료